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Visual disturbances are a common side-effect of many antiepileptic drugs. Non-specific retino- and neurotoxic visual abnormal-
ities, that are often reported with over-dosage and prolonged AED use, include diplopia, blurred vision and nystagmus. Some
anticonvulsants are associated with specific visual problems that may be related to the mechanistic properties of the drug, and
occur even when the drugs are administered within the recommended daily dose. Vigabatrin, a GABA-transaminase inhibitor, has
been associated with bilateral concentric visual field loss, electrophysiological changes, central visual function deficits including
reduced contrast sensitivity and abnormal colour perception, and morphological alterations of the fundus and retina. Topiramate,
a drug that enhances GABAergic transmission, has been associated with cases of acute closed angle glaucoma, while tiagabine,
a GABA uptake inhibitor, has been investigated for a potential GABAergic effect on the visual field. Only mild neurotoxic
effects have been identified for patients treated with gabapentin, a drug designed as a cyclic analogue of GABA but exhibiting an
unknown mechanism while carbamazepine, an inhibitor of voltage-dependent sodium channels, has been linked with abnormal
colour perception and reduced contrast sensitivity. The following review outlines the visual disturbances associated with some
of the most commonly prescribed anticonvulsants. For each drug, the ocular site of potential damage and the likely mechanism
responsible for the adverse visual effects is described.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Epileptologists administer antiepileptic drugs with
the combined aim of managing seizures, minimising
side-effects and maintaining an acceptable quality
of life for the patient. All of the antiepileptic drugs
(AEDs) commonly used to control seizures in the UK
are associated with some adverse effects; these range
from mild effects such as nausea and weight gain, to
more serious life-threatening complications including
renal, hepatic and cardiovascular changes1. The num-
ber of marketed AEDs has increased considerably over
the last decade, with many of the newer agents elicit-
ing fewer side-effects2; visual disturbances, however,
remain a relatively common occurrence (Table 1).
Visual disruption in patients diagnosed with
epilepsy may be attributable to either the disease
process3, or the anticonvulsant therapy prescribed
to control the seizures. While many mild visual dis-
turbances such as diplopia, nystagmus and blurred
vision may simply be an early neurotoxic compli-
cation of extended treatment or dosage, other, more
specific ocular complaints may be related to the
unique mechanistic properties of the drug and can
occur even when administered at therapeutic levels.
Steinhoff et al.4 recommended the retina as a parallel
model to study the mechanistic properties of anti-
convulsant therapy on cortical and cerebral function.
The retina is ontogenically part of the brain, and
studies have shown that epileptogenic mechanisms
including GABAergic and glutamatergic neurotrans-
mission and ion-dependent membrane conductance
are mediators of retinal signal transmission4, 5. The
following review will outline the main visual effects
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Table 1: Antiepileptic drugs (listed alphabetically), their mechanism of action and visual side-effects.
AED Main mechanism of action Visual side-effects
Acetazolamide (old) Carbonic anhydrase inhibitor Enhanced ocular blood flow
Decreased IOP
Benzodiazepine
AEDs (old)
Enhanced GABA-mediated inhibition via
benzodiazepine receptor
Blurred vision, ERG and VEP changes,
maculopathy, improved nystagmus
Carbamazepine (old) Inhibition of voltage-dependent Na+ channels Blurred vision, diplopia, abnormal colour
perception, nystagmus, oscillopsia,
photosensitivity, altered VEPs
Ethosuximide (old) Altered neurotransmitter release Dyskinesia, photophobia, myopia
Control of Ca2+ into nerve terminals
Modulation of Na+, and Cl− conductance
Felbamate (new, but
little used)
Uncertain mechanism Diplopia, nystagmus
Blocks NMDA currents facilitating a GABAergic
response
Gabapentin (new) Designed as GABA agonist (?)
Possible GABA mechanism (?)
Glutamate receptor effect (?)
Blurred vision, nystagmus, diplopia, some visual
electrophysiological changes. Impaired critical
flicker frequency, improved post-adaptation
thresholds and nystagmus
Lamotrigine (new) Reduced glutamate release by inhibiting
voltage-sensitive Na+ channels
Blurred vision, diplopia, some visual
electrophysiological disturbances, nystagmus
Levetiracetam (new) Unknown mechanism Diplopia
May selectively prevent hypersynchronisation
Oxcarbmazepine
(new in the UK)
Block voltage-sensitive Na+ channels Diplopia, blurred vision
Increased K+ conductance and modulation of
high-voltage Ca2+ channels
Phenobarbitone (old) Potentiation of GABA-A receptor activation No major visual effects reported
Phenytoin (old) Inhibition of voltage-dependent Na+ channels Dyskinesia, nystagmus, ophthalmoplegia, blurred
vision, disturbed colour perception
Primidone (old) Unclear mechanism related to drug metabolism Diplopia, nystagmus
Potentiation of GABAergic synaptic activity
Sodium valproate (old) Enhanced GABAergic inhibition (?) Some reports of abnormal colour perception and
altered VEPsInhibition of voltage-dependent sodium channels
Topiramate (new) Enhances GABA Cl− channels Diplopia, acute myopia and angle closure glaucoma
Positive effect on GABA-A receptor
Kainite inhibition
Carbonic-anhydrase inhibition
State-dependent sodium channel-blocking action
Tiagabine (new) GABA reuptake inhibitor Abnormal colour perception, blurred vision,
nystagmus, diplopia
Vigabatrin (new) GABA-transaminase inhibitor enhances inhibitory
neurotransmission
Diplopia, nystagmus, peripheral visual field loss,
colour perception abnormalities, retinal
abnormalities, optic nerve pallor, visual
electrophysiological changes, reduced contrast
sensitivity, reduced ocular blood flow
associated with anticonvulsant therapy; the drugs
will be grouped by their mechanisms of action,
with special attention to the new GABAergic acting
drugs.
GABAergic CELLS OF THE RETINA
-Aminobutyric acid (GABA) is the main inhibitory
neurotransmitter in the mammalian brain6 influencing
between 60 and 70% of all synapses7. Investigations
have revealed that GABA is similarly important in
retinal neural inhibition where approximately 40% of
all retinal cells are immunoreactive to it8. Tradition-
ally, light microscopic findings have led to the human
retina being described as 10 functional layers of cells
(Fig. 1). Of these, subpopulations of amacrine and hor-
izontal cells, bipolar cells, interplexiform cells, Müller
cells and retinal ganglion cells have been described as
GABAergic8–11.
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Fig. 1: Anatomy of the human retina.
GABA is synthesised in the presynaptic nerve ter-
minal from glutamate by the enzyme glutamic acid
decarboxylase (GAD). GABA containing vesicles
release the neurotransmitter into the synaptic cleft
where it diffuses across to bind with GABA recep-
tors on the post-synaptic neuron. Three heterogenous
receptors are known to exist in the vertebrate retina
and central nervous system; GABA-A, GABA-B and
GABA-C subtypes10. GABA-A and GABA-C re-
ceptors are particularly abundant in the retina12, 13
where receptor binding triggers the opening of chlo-
ride channels which is inhibitory to neuronal firing.
GABA-C receptors differ markedly from the other
subtypes in two main ways: (1) they are highly sen-
sitive to GABA14, thus even at low concentrations
the neurotransmitter can initiate a response; and (2)
they initiate a sustained response to GABA, rather
than a transient response which is true for GABA-A
receptors10. The inhibitory action of GABA is lim-
ited via active reuptake into the presynaptic nerve
terminals and surrounding glial cells. To date, four
distinct high-affinity GABA transporters (GAT) have
been cloned6, three of which have been identified in
the vertebrate retina15, 16.
There are several ways in which anticonvulsant
drugs may enhance inhibitory neurotransmission
(Fig. 2): GABA-mediated increases in chloride con-
ductance may be enhanced; GABA levels may be
raised by stimulating the enzyme GAD; the release
of GABA may be enhanced; and, the reuptake and
degradation of GABA may be inhibited.
AEDs UTILISING GABAergic MECHANISMS
Vigabatrin
Visual field loss
Vigabatrin (-vinyl GABA) elicits an antiepileptic ef-
fect by binding irreversibly to GABA-transaminase17,
thereby increasing GABA levels and enhancing in-
hibitory neurotransmission in the brain. Vigabatrin
has been targeted largely at the management of par-
tial seizures and infantile spasms and was used un-
til the late 1990s when isolated reports of concentric
peripheral visual field loss and visual electrophysio-
logical abnormalities began to emerge.
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Fig. 2: Functional sites of action for GABA-acting AEDs (adapted from Leach and Brodie 1998)7. The mechanisms of action
for sodium valproate and felbamate, which are thought to be GABA-influencing, but are less clear, are not included.
Vigabatrin-associated visual field loss has been iden-
tified with both kinetic and static perimetry and is
unique, characteristically presenting as bilateral con-
centric nasal constriction with temporal and central
sparing18, an example of which is shown in Fig. 3.
This distinct visual field abnormality is unusual as bi-
nasal visual field loss attributable to other causes is
rare; optic neuritis, including the toxic tobacco form,
can occasionally yield bilateral visual defects19, how-
ever, these are readily distinguishable from vigabatrin-
related defects as they include cecocentral scotoma.
Recent estimates of vigabatrin-associated visual field
loss suggest that approximately 30% of epilepsy pa-
tients receiving the anticonvulsant at normal therapeu-
tic levels present with abnormalities18, 20, 21, although
this figure varies with some authors reporting higher
prevalences22–25, and others reporting slightly lower
prevalences26–28. Gender differences have been re-
vealed in some studies, suggesting that men receiving
vigabatrin are more susceptible to visual field con-
striction than women18, 27, 29, however, this is not a
consistent finding21. The vast majority of vigabatrin-
associated visual field constriction cases are asympto-
matic18, 20, 21, 23. In clinical ophthalmology, patients
with visual field defects often remain asymptomatic
until the defect impinges on, or close to, fixation; this
is particularly likely in the case of binasal defects
where the preserved temporal visual field in each eye
enables patients to retain good mobility.
Longitudinal investigations of vigabatrin-associated
visual field loss have reported the defects to be
permanent30–32, persisting even after patients are
withdrawn from the drug27, 33. The majority of pa-
tients are withdrawn from vigabatrin with the advent
of visual field loss, however in a 1-year follow-up of
patients with definite visual defects who continued to
take vigabatrin, no evidence of progressive loss was
found on repeated testing34. A few isolated cases of
visual field improvement following cessation of viga-
batrin have been described in children24, 35, however,
these findings are rare and may well be attributable
to learning effects.
Several studies have questioned whether visual
field damage correlates with vigabatrin cumulative
dose with many reporting a significant relation-
ship26, 28, 31, 32, 36–38, and others failing to demons-
trate any correlation21, 27, 39. The significance of drug
interactions arising from adjunctive therapy has also
been addressed. In a summary of a series of vigabatrin-
related investigations Sorri21 reported no significant
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Fig. 3: Vigabatrin-associated visual field loss (white–white 24-2 full threshold, grey scale and pattern deviation plots).
difference between the visual field defects of epilepsy
patients receiving vigabatrin as monotherapy com-
pared to those receiving it as add-on therapy. How-
ever, a study that compared two groups of epilepsy
patients treated with vigabatrin and additional ther-
apy of carbamazepine or sodium valproate, identified
more severe visual field constriction in the latter
group40. Sodium valproate influences the GABAergic
system and it is possible that the combined effect
of two anticonvulsants that influence GABA may be
more detrimental to vision than vigabatrin in combi-
nation with a none GABAergic acting AED such as
carbamazepine.
The reason why only some vigabatrin-treated in-
dividuals present with visual field disruption while
others remain unaffected is unclear. Hisama et al.41
suggested that GABA toxicity, or the effect of a
metabolite in combination with a predisposing geno-
type, may be responsible. Thus far, a genetic mutation
has not been identified, however a common poly-
morphism has been cloned which may be suggestive
of genetic involvement41. An alternate explanation
may be offered by altered ocular haemodynamics;
decreased retinal and pulsatile ocular blood flow has
been described in patients with epilepsy compared
to normal healthy volunteers42, 43. This finding ap-
pears to be further exacerbated in vigabatrin-treated
epilepsy patients compared with those treated with
other AEDs42 and it is conceivable that pre-existing
ischaemia or a GABA-mediated vascular effect may
be contributory to visual disruption44.
Colour perception
The short-wavelength (blue) sensitive cones are highly
sensitive to acquired colour deficiencies and disrup-
tion to these cells can produce short-wavelength (tri-
tan) defects. Toxic injury to the medium-wavelength
(green) sensitive cones and long-wavelength (red)
sensitive cones is less common, however, damage
to these pathways can result in medium-wavelength
(deutan) or long-wavelength (protan) defects, re-
spectively. Numerous investigational methods exist
for the measurement of colour perception that vary
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substantially in their depth of exploration. While Ishi-
hara and other standard psuedoisochromatic plates
yield relatively simple interpretations of colour vi-
sion, the more comprehensive Farnsworth-Munsell
(FM) 100-hue test provides a detailed assessment of
chromatic function at the fovea. In addition to en-
abling the separation of individuals into classes of
superior, average and low colour discrimination, the
FM 100-hue test also facilitates the measurement of
zones, or axes, of colour confusion in colour defective
patients.
Abnormal colour perception has been demonstrated
with Ishihara plates, other standard pseudoisochro-
matic plates, and the FM 100-hue in some patients
treated with vigabatrin45–47. Nousiainen et al.47 re-
ported acquired colour vision disturbances in epilepsy
patients treated with vigabatrin-monotherapy that pre-
dominated in the tritanoptic axis and were associated
with the temporal extent of visual field loss. A later
study, which investigated the effect of a single dose of
vigabatrin on normal healthy volunteers using colour
visual evoked potential tests together with colour
perimetry, described a selective tritanoptic visual im-
pairment consistent with GABAergic inhibition at
the retinal level48. This important study of normal
healthy subjects confirms the existence of vigabatrin-
mediated colour disturbances that are entirely drug-
induced and not related to the epilepsy disease process;
however, whether the effect was short-lived or ongo-
ing was not reported48.
Steinhoff et al.4 employed a battery of clinical and
psychophysical tests to assess visual perception in nor-
mal healthy volunteers who had received a single AED
dose. The results for vigabatrin were somewhat con-
flicting: no observable change in the D15 colour vision
test was noted, however, increased post-adaptation,
increment and transient tritanopia thresholds did oc-
cur consistent with augmentation of GABA properties.
The authors concluded that the observed changes were
a function of neurophysiological alterations related to
the specific mechanistic effect of vigabatrin, and not
simply a neurotoxic effect. In a related study, the same
battery of tests was applied to a group of epilepsy pa-
tients chronically treated with a mixture of vigabatrin
and carbamazepine49; similar findings were reported,
however, the existence of similar changes for other
non-GABAergic acting drugs led to difficulty distin-
guishing between mechanistic and general neurotoxic
effects.
In a separate investigation of colour discrimination
using the FM 100-hue test in epilepsy patients who
had undergone add-on treatment with vigabatrin, 33%
of patients exhibited below average colour discrimina-
tion and in each case the zone of colour confusion was
unresolved39. This finding suggested a diffuse, or gen-
eralised, colour perception deficit consistent with toxic
damage affecting all chromatic pathways equally,
and may have been the product of complex drug
interactions.
Contrast sensitivity
Contrast sensitivity, the ability of the eye to detect ob-
jects of varying spatial frequencies and thus contrast,
is a useful measure of foveal function. Nousiainen
et al.50 measured contrast and glare sensitivity in a
vigabatrin monotherapy-treated epilepsy group and
reported impaired contrast function in patients with
concentric white–white visual field loss. Surveys of
children treated with vigabatrin have shown that up to
half present with subnormal visual acuity and reduced
contrast sensitivity where abnormal electroretinogram
(ERG) responses co-exist51, 52. When the CSV-1000
was employed to assess spatial contrast sensitivity
in a group of epilepsy patients who had received
vigabatrin polytherapy, abnormal contrast sensitivity
was apparent in 66% of patients tested; in each case
the defects were most predominant at higher spatial
frequencies39.
Central visual field loss
While there is extensive evidence of visual field loss
in vigabatrin-treated patients, the existence of colour
perception disturbances and contrast sensitivity im-
pairment implies that the area within the central 10◦
of the retina is also affected. Anatomically, it follows
that a diffuse toxic effect would encompass central as
well as peripheral retinal areas. Central white–white
visual field defects within the innermost 10◦ have not
been reported for vigabatrin-treated epilepsy patients,
however, it is known that in some optic and retinal
neuropathies the use of short-wavelength automated
perimetry (SWAP), which preferentially stimulates
subpopulations of the parvocellular pathway, enables
the detection of subtle defects before conventional
white–white perimetry53. Furthermore, it follows that
an acquired tritanoptic colour deficiency previously
observed in vigabatrin-treated patients47 might be
expected to yield abnormal results to SWAP, par-
ticularly in the central visual field corresponding to
foveal function.
Daneshvar et al.20 reported SWAP 30-2 defects
in eight of nine vigabatrin-treated epilepsy patients,
while an investigation of SWAP in the central 10◦
of a group of vigabatrin-treated epilepsy patients re-
vealed abnormal results in the majority39. It was sug-
gested that the subtle defects preferentially detected
by SWAP may have occurred as a result of reduced
redundancy: where the relative paucity of the blue
cones result in an impaired functional response that
is detectable earlier than other pathways.
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Morphological changes
Laboratory investigations using animal models have
identified intramyelinic oedema following prolonged
vigabatrin administration in some species54, 55. Hu-
man histological and clinical studies, however, have
failed to find any direct or indirect evidence of in-
tramyelinic oedema following vigabatrin treatment56.
Morphological change in the retina has been identi-
fied peripherally and centrally in vigabatrin-treated
patients. A range of non-specific abnormalities have
been observed including narrowing of the retinal
arterioles45, atrophy and tessellation of the periph-
eral retina30, surface wrinkling retinopathy of the
macula45, abnormalities of the retinal pigment epithe-
lium, irregularities of the macula reflex, and pallor of
the optic nerve30, 57, 58. Of the aforementioned abnor-
malities, the most recurrent ophthalmic sign reported
in vigabatrin-treated patients is optic disc pallor.
The results of a pathological report for a 41-year-old
male with a history of complex partial seizures who
had been treated with vigabatrin and subsequently
developed bilateral visual field constriction, further
clarified the morphological effect of the drug59. The
patient exhibited signs of peripheral retinal atrophy
together with a loss of retinal ganglion cells and nerve
fibres of the optic nerve, chiasm and optic tracts; no
evidence of intramyelinic oedema could be found. It
was suggested that the retinal ganglion cells repre-
sented the primary site for toxic injury; furthermore,
it was the opinion of the author that the extent of
cellular damage would have meant that the presenting
visual field loss was irreversible59.
Electrophysiological changes
The early animal findings of vigabatrin-related in-
tramyelinic oedema accompanied by reversible alter-
ations in somatosensory and visual evoked potentials
(VEPs), acted as a catalyst for human electrophys-
iological studies. The majority of investigations
revealed no alteration to VEPs in vigabatrin-treated
patient groups and only isolated cases of delayed VEPs
and reduced amplitudes have been reported20, 45.
This suggests that vigabatrin-associated toxicity is
unlikely to be localised in the visual pathway or cor-
tex. Instead, visual electrophysiological disturbances
in patients receiving vigabatrin are supportive of a
retinal locus of abnormality with defects being lo-
calised to the inner and outer retina, particularly at
the level of the Müller cells60 which are known to
be GABAergic. Two main vigabatrin-related visual
electrophysiological effects have been proposed:
(1) A transient effect on the electro-oculography
(EOG) Arden index (light and dark ratios) sug-
gestive of raised GABA levels that ceases when
the drug is withdrawn61, 62. It has been suggested
that this effect may indicate drug efficacy rather
than toxicity63.
(2) A progressive effect that results in abnormalities
of the ERG and is thought to be associated with
a risk of visual field loss. This effect persists
after the drug is withdrawn.
The most consistent ERG changes associated with
vigabatrin-attributed visual loss include increased
latency of the ERG photopic b-wave, decreased ampli-
tude of the b-wave, reduced or absent oscillatory po-
tentials and abnormalities of the cone function (30 Hz)
flicker response18, 23, 25, 45, 61, 62, 64–66. Abnormal mul-
tifocal ERGs have also been identified in vigabatrin
patients with co-existing visual field defects25, 62, 65,
however, the site of abnormality is not always re-
stricted to the area corresponding to visual field
damage. This, together with reports of altered cone
responses25, 45, suggests that vigabatrin-mediated tox-
icity is not confined to the peripheral retina, but is
widespread encompassing central areas.
The usefulness of visual electrophysiological tests
to predict and monitor vigabatrin-associated visual
field loss has been considered and is particularly
relevant when visual field testing proves difficult,
unreliable, or impossible. Hardus et al.67 questioned
the usefulness of electrophysiological investigations
for predicting visual field loss when abnormalities
of the ERG and EOG were only observed in 57 and
50% of epilepsy patients with vigabatrin-related vi-
sual field loss. More recently, however, in a study of
29 vigabatrin-treated epilepsy patients of which 68%
were found to have visual field constriction, 90% of
field-defective patients had accompanying EOG and
ERG changes38. Furthermore, of the remaining 32%
of patients without demonstrable visual field loss,
64% yielded abnormal electrophysiology results. On
the basis of these findings, the authors concluded that
visual electrophysiological testing does provide an
accurate method for monitoring the direct effect of
vigabatrin on the outer retina.
Vigabatrin is particularly useful in the treatment of
infantile spasms, but perimetry testing in children,
particularly those under a developmental age of 9
years, has proved a clinical challenge. Recently, an
electrophysiological approach has been applied util-
ising a field specific VEP consisting of a central and
peripheral stimulus that has a sensitivity of 75% and
specificity of 87.5% for identifying patients with ab-
normal visual fields68. When the authors compared
perimetry results with conventional ERG findings
in 12 patients, only the 30 Hz flicker response was
helpful in predicting visual field loss and it was sug-
gested that a field specific VEP approach provides
a sensitive, specific and well-tolerated technique for
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confirming vigabatrin-associated visual field loss in
children68.
Treatment considerations
Kalviainen and Nousiainen63 recommended that viga-
batrin should only be used in combination with other
AEDs for patients with resistant epilepsy when all
other appropriate combinations have proved unaccept-
able or intolerable. When treatment with vigabatrin is
indicated, visual field testing should be carried out at
the start of treatment and at regular time intervals. For
children with infantile spasms, the benefits of viga-
batrin monotherapy may outweigh the risks. Recently
reported findings from an investigation of 91 Finnish
children suggested that the prevalence of visual field
constriction in children treated with vigabatrin is lower
than for adults28, however, this needs to be verified.
Topiratmate
Topiramate is a multifaceted drug that utilises sev-
eral mechanisms to elicit an antiepileptic effect: (1) a
state-dependent sodium channel-blocking action69;
(2) enhanced GABA-mediated chloride fluxes across
the post-synaptic membrane70; (3) positive modula-
tion on the activity of GABA-A receptors71; (4) kai-
nite inhibition to activate the kainite/AMPA subtype
of the excitatory amino acid receptor72; (5) carbonic
anhydrase inhibition (mild effect). Topiramate is gen-
erally administered as adjunctive therapy for children
aged 2–16 years and adults with partial onset seizures
or primary generalised tonic–clonic seizures73.
In a review of topiramate efficacy and tolerability,
visual disturbances were among the more common ad-
verse symptoms reported74. Topiramate has recently
been reported to cause acute myopia and secondary
closed angle glaucoma without pupillary block in
a small proportion of patients73, 75. These findings
are more common in females, occur within the nor-
mal therapeutic range and usually appear within 10
days of medication onset76. The US Food and Drug
Administration (2001) announced that following
post-marketing data of more than 825 000 patients
with topiramate, 22 adults and 1 child have been re-
ported to develop ocular symptoms. The symptoms
usually occur within the first month of therapy where
patients report an acute onset of decreased visual acu-
ity and/or ocular pain. Ensuing ocular examination has
revealed myopia, ocular hyperemia, shallowing of the
anterior chamber and elevated intraocular pressure,
with or without pupil dilation; choroidal effusions
have also been described73. It has been suggested
that supraciliary effusion and ciliary body swelling
may displace the lens and iris anteriorly, secondar-
ily resulting in angle closure glaucoma. While the
anticonvulsant properties of topiramate are clear, the
reason why a minority of patients present with severe
visual side-effects remains to be determined although
topiramate has been detected in the vitreous77.
Steinhoff et al.49 investigated the effect of combined
carbamazepine and topiramate therapy on the visual
perception of epilepsy patients compared to controls
and reported impaired colour perception with the D15
test, critical flicker fusion, post-adaptation thresholds
and transient tritanopia. The authors postulated that
the changes were mainly the result of non-specific
retino- or neurotoxic effects, and were not mechanistic.
Tiagabine
Tiagabine, is a new generation drug that acts as a se-
lective and specific inhibitor of both neuronal and glial
presynaptic GABA reuptake. As is the case with most
AEDs, blurring of vision and nystagmus, which are
often associated with over-dosage and neurotoxicity,
were amongst the side-effects reported in tiagabine
clinical trials78, 79. In a review of 42 epilepsy patients
who took tiagabine for longer than 6 months in two
long-term studies, 39% reported diplopia, difficulty
with focusing, and blurring79.
Although vigabatrin has been identified in the rat
retina, the same experiment did not reveal an accumu-
lation of tiagabine80. However, in view of tiagabine’s
GABAergic action, some investigators have queried
whether the drug is associated with visual field loss.
In a review of 2531 tiagabine clinical trials records,
eight patients tested by confrontation exhibited visual
field disruption81. Previous brain lesions accounted
for the visual field loss in two of the patients, and of
the remaining six, the abnormality either resolved nat-
urally or with AED intervention. This study provided
reassurance that tiagabine is a visually safe drug, but
was limited by the insensitive method used for visual
field testing. In an abstract published the following
year, 6 out of 12 patients treated with tiagabine were
diagnosed with visual field defects that were report-
edly similar to those observed for vigabatrin82. This
publication raised concern and was subsequently a
subject of discussion83. A number of studies have
now concluded that tiagabine does not cause visual
field or sensory defects84–87 and it is possible that
previously described abnormalities may have been
the result of methodological differences88. Kaufman
et al.89 described a single case of reversible asymp-
tomatic visual field loss in a psychiatric patient with
bipolar disorder treated with tiagabine. It is likely,
however, that this complicated case represents an iso-
lated incident with too many confounding variables.
Acquired colour vision defects have been described
in 50% of patients treated with tiagabine, a number
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not dissimilar to that seen with some other AEDs86.
Abnormal contrast sensitivity measures have not been
reported86. Finally, although a review of the litera-
ture has not revealed any evidence for abnormal vi-
sual electrophysiological responses in humans treated
with tiagabine, animal studies using nipecotic acid, of
which tiagabine is an analogue, have reported influ-
ences on the photoptic ERG and horizontal cells90, 91.
Sodium valproate
The antiepileptic mechanism of action elicited by
valproate is unclear, but may form the sum of several
convergent mechanisms including enhanced GABAer-
gic transmission92 and blocked voltage-dependent
sodium channels93. Overall, reports of abnormal
visual function with patients treated with sodium
valproate are scarce. In a study that employed the
FM 100-hue test to investigate colour vision in three
groups of epilepsy patients undergoing different AED
treatments, increased error scores were observed in
sodium valproate-treated patients when compared
to normal subjects94; impairment of chromatic and
achromatic increment discrimination and increased
post-adaptation thresholds where also described94.
Two later studies, which investigated colour percep-
tion in patients exposed to sodium valproate, yielded
normal results95, 96.
Sodium valproate has been reported to suppress
VEPs in rats97, 98 via a GABAergic mechanism; al-
tered VEPs have also been reported in children99, 100
and adolescents100 treated with the drug. ERG pa-
rameters, however, appear to be unaffected101.
Ozkul et al.101 found no evidence of visual field
loss or altered visual acuity in an epilepsy group
treated with sodium valproate. An isolated case of a
25-year-old woman who had been treated with sodium
valproate and later with carbamazepine, who pre-
sented with visual field loss similar to that observed in
patients treated with vigabatrin, has been reported102.
The authors suggested that a genetic predisposition to
aspecific inhibition of several aminotransferases may
have been responsible for this particular case, and that
a genetic basis may also help to explain the visual
effects of other AEDs on vision in some individuals.
Felbamate
Felbamate is a new AED that acts on both excitatory
and inhibitory brain mechanisms by blocking currents
evoked by N-methyl-d-aspartate (NMDA) and facili-
tating GABAergic responses103. Its use is limited by
side-effects. In a review of the therapeutic efficacy of
felbamate, diplopia was reported as a fairly common
central nervous system disturbance104. An isolated
case of reversible downbeat nystagmus and ataxia has
been reported following felbamate intoxication105.
Benzodiazepines
Benzodiazepine AEDs (diazepam, clonazepam and
clobazam) act at distinct allosteric binding sites on the
GABA-A receptor-chloride ionosphore, commonly
termed the benzodiazepine receptor106, to enhance
GABA-mediated increases in chloride conductances
by increasing the frequency of channel opening.
There is a well-documented affinity between benzo-
diazepines and the mammalian retina107, 108. Clon-
azepam has been associated with improved acquired
nystagmus109 and has been suggested as a possi-
ble treatment for nystagmus-induced oscillopsia110.
Clonazepam has also been investigated for an effect
on VEPs in humans and animal models111–113 where,
compared to placebo, clonazepam reduced VEP am-
plitudes in young healthy men113.
Stafanous et al.114 carried out an ophthalmic ex-
amination for 30 patients treated with long-term
benzodiazepine medication. Nineteen of the patients
complained of symptoms of irritation, blurred vision
or difficulty with reading, however, on examination
reduced visual acuities were only present in two pa-
tients with a history of amblyopia. Of the group, 43%
had retinal abnormalities, but no retinal functional
ERG abnormalities could be attributed to the med-
ication, dose or duration of treatment. In an earlier
study, Jaffe et al.115 presented baseline ERG data for
a group of healthy volunteers receiving varying doses
of diazepam under dark and light adaptation and con-
cluded that diazepam produces an attenuating effect
on the ERG that is more pronounced under conditions
of light. The ERG effects, mediated from rods and
cones, may be explained by the GABA-potentiating
effect of diazepam within the inner nuclear layer
of the retina which may increase retinal dopamine
and act on the photoreceptors116. An investigation
of pattern-elicited VEPs revealed parallel amplitude
reductions in both humans and rats treated with high
doses of diazepam117, however, no changes were ob-
served in the pattern-reversal VEPs of healthy humans
receiving a single dose of the drug118. Reduced EOG
potentials have also been identified in humans follow-
ing a single dose of diazepam119 which is suggestive
of diazepam modulation of the outer retina120.
A single case of maculopathy in a patient prescribed
diazepam to control anxiety has been reported120.
Diazepam has also been associated with acute glau-
coma121 and allergic conjunctivitis122. Reports of
visual field constriction following diazepam are
scarce; a single case of severe bilateral visual loss in a
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patient administering 100 mg of diazepam, which nor-
malised following cessation of the drug was ascribed
to a possible GABA-mediated effect on the retina or
visual cortex123. This individual case was based on
just two visual field examinations and the possibility
of a learning effect was not discussed. Nystagmus-
induced by stimulation of the lateral geniculate-body
in the rabbit has been shown to be depressed with
diazepam, however, the resulting after-stimulus nys-
tagmus was prolonged; it has consequently been sug-
gested that diazepam may act on central nystagmus
through mechanisms mediated by GABA124.
Barbiturates
Similar to benzodiazepines, the barbiturate AEDs (pri-
midone and phenobarbitone) enhance GABA-media-
ted increases in chloride conductances by prolonging
the duration of channel opening. More specifically,
phenobarbitone exhibits a mechanism of action that
augments chloride-channel responses to GABA125, re-
duces synaptic responses to glutamate125 and blocks
voltage-activated calcium126. Reports of ocular and
visual abnormality in patients treated with barbitu-
rates are sporadic. A single case of induced periodic
alternating nystagmus, which was attributed to barbi-
turate intoxication, was described in a male patient
treated with both primidone and phenobarbitone127.
Nordmann et al.128, 129 described four cases of tunnel
vision in epilepsy patients treated with AEDs; three
of the patients had received vigabatrin and one had
received a mixture of phenobarbitone and progabide,
an agonist of post-synaptic GABA receptors, all of
which interact with the GABAergic pathway. The au-
thors hypothesised that the retinal toxicity triggered by
chronically increased GABA transmission may occur
with GABA-mimetic drugs.
Brinciotti130 carried out a visual electrophysiologi-
cal investigation of children with chronic high serum
levels of phenobarbitone and noted increased P2 la-
tency of the VEP that decreased as the drug serum
level reduced. In a later study of visual and auditory
function in a group of epileptic children and adoles-
cents who had undergone monotherapy treatment with
phenobarbitone, no abnormal manifestations were ob-
served compared to a healthy control group100.
AEDs UTILISING NON-GABAergic
MECHANISMS
Carbamazepine
Carbamazipine is a widely used AED that works by the
inhibition of voltage-dependent sodium channels131.
Carbamazepine has been reported to affect saccadic
eye movements132 and has been associated with iso-
lated cases of downbeat nystagmus and oscillopsia
(illusionary movements of objects)133. When pre-
scribed outside of the therapeutic dose, blurred vision,
diplopia and nystagmus may occur.
Colour vision disturbances have been reported in
epilepsy patients treated with carbamazepine47, 94,
however, this finding is not universal49 and studies of
the effect of carbamazepine on healthy subjects have
yielded conflicting results. Steinhoff et al.4 delivered
a single oral dose of carbamazepine to healthy normal
volunteers and did not find any adverse effects on
colour perception with the desaturated Lanthony 15
test. In contrast, abnormalities in non-standard colour
perimetry that were suggestive of mild disturbances
of both the red and blue chromatic pathways have
been reported following a single carbamazepine dose
in healthy subjects134.
Mildly increased error scores, without a clear axis
of colour confusion, have been observed with the FM
100-hue test in a group of epilepsy patients treated
with carbamazepine monotherapy (n = 14) when
compared to a normal subject group94. A later study,
utilising the same technique, described blue-yellow
colour perception deficiencies in carbamazepine-treat-
ed epilepsy patients, whereas untreated patients main-
tained normal colour vision95. Steinhoff et al.49 using
a less comprehensive technique for assessing colour
perception, did not note any abnormalities for a group
of 18 carbamazepine monotherapy-treated epilepsy
patients compared to healthy controls.
Sartucci et al.135 measured contrast sensitivity in
28 patients with uncontrolled epilepsy that had un-
dergone long-term treatment with carbamazepine,
and reported loss for all spatial frequencies tested
compared to control subjects. Following the addition
of vigabatrin, a recovery in contrast sensitivity was
reported; this finding is at odds with other studies
that have implicated vigabatrin as a contender for
impaired contrast sensitivity, and might simply reflect
the effect of controlling seizure activity in that patient
group. Conversely, no abnormalities in contrast and
glare sensitivity were observed in a carbamazepine
monotherapy-treated epilepsy group50.
A possible retinotoxic effect has been suggested by
Nielsen and Syversen136 who described two patients
with reversible retinal pigment epithelial changes fol-
lowing 7 years of carbamazepine therapy. The wide
use of this drug in epilepsy and other neurological
conditions, together with the absence of similar re-
ported cases suggests that morphological changes due
to carbamazepine are extremely rare.
Few reports have identified visual electrophysiolog-
ical changes in response to carbamazepine, however, a
recent study did note increased VEP latencies in both
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children and adolescents treated with the drug100. In
an investigation of the visual and ocular outcome of 43
children exposed to prenatal AEDs, the most common
of which was carbamazepine, two children presented
with severe microphthalamus and one with unilateral
optic disc coloboma137.
Oxcarbazepine
Oxcarbazepine is a keto-analogue of carbamazepine
which is almost immediately converted to a 10-mono-
hydroxy derivative, its main metabolite103. The an-
ticonvulsant action of oxcarbazepine is uncertain,
however, it may block voltage-sensitive sodium chan-
nels, resulting in stabilisation of hyperexcited neural
membranes, inhibition of repetitive neuronal firing,
and decreased propagation of synaptic impulses. Also,
increased potassium conductance and modulation of
high-voltage-activated calcium channels may con-
tribute to the anticonvulsant effects. Oxcarbazepine
has similar properties to carbamazepine, but has a
better tolerability profile.
Some of the most common adverse effects associ-
ated with oxcarbazepine are related to the central ner-
vous system and include, amongst others, diplopia138.
In an open label pilot study of oxcarbazepine of
10 in-patients under evaluation for epilepsy surgery,
blurred vision was reported in 10%139. The effect of
oxcarbazepine and carbamazepine on saccadic and
smooth muscle eye movements has been consi-
dered140: while oxcarbazepine only induced negligible
alterations on the eye movement parameters measured,
the effects of carbamazepine were more apparent.
Gabapentin
Gabapentin is an amino acid designed as a cyclic
GABA analogue to penetrate the blood–brain bar-
rier and act as a GABA agonist. Extensive studies
have failed to demonstrate an effect of gabapentin
on GABA receptors, GABA uptake or GABA
metabolism, yet a GABAergic mechanism has not
been ruled out. In a study that assessed the efficacy
and tolerability of gabapentin in 599 epilepsy pa-
tients, blurred vision and diplopia were among the
adverse effects reported141. In an earlier study, 13.5%
of patients treated with gabapentin reported visual
problems142. In Steinhoff et al.’s4 study of visual
perception in healthy subjects receiving a single dose
of gabapentin, visual acuity and colour visual percep-
tion with the D15 test remained unaffected while an
improvement in post-adaptation thresholds together
with an impairment of critical flicker frequency was
described. Although these changes may have been
due to non-specific neurotoxic effects, the authors
considered this unlikely and suggested a possible
antiglutamatergic mechanism. In a follow-up paper,
where the same visual tests were applied to a group
of epilepsy patients receiving carbamazepine and
gabapentin, no significant differences were noted for
post-adaption thresholds or critical flicker frequencies
compared to control patients49.
In a small study of the electrophysiological con-
sequences of gabapentin, three out of seven patients
treated exhibited abnormal VEPs and one patient pre-
sented with an abnormal pattern ERG143. It was sug-
gested that an individual disposition to toxic effects
on the transmitter function of the optic nerve might
be responsible.
Gabapentin has been shown to elicit a beneficial
effect on acquired pendular nystagmus resulting in
improved vision due to changes in ocular oscilla-
tions144, 145. Initially a GABAergic mechanism was
hypothesised to explain the improved nystagmus, but
a study that compared the effect of a single dose
of gabapentin with a one off dose of vigabatrin on
acquired nystagmus in multiple sclerosis patients
only observed a beneficial effect with gabapentin146.
The authors suggested an alternate explanation for
gabapentin’s therapeutic effect involving a possible
interaction with cerebral glutamate transmission by
inhibition of NMDA receptors.
Phenytoin
Phenytoin is a neuronal sodium channel antagonist131
used widely for the treatment of both complex par-
tial and generalised epileptic seizures. Phenytoin, in
particular, is known to influence the vestibulo-ocular
system. In a study that investigated the effect of
phenytoin toxicity in healthy volunteers, both horizon-
tal gaze-evoked nystagmus and vertical gaze-evoked
nystagmus were identified147. More worryingly, iso-
lated cases of total external ophthalmoplegia have also
been described in some phenytoin-treated patients,
fortunately however, this condition is short-lived and
reversible148.
In a detailed investigation of the effect of AED
therapy on chromatic and achromatic visual percep-
tion, patients receiving phenytoin exhibited the most
abnormalities, particularly for the FM 100-hue test
where elevated error scores, without a clear axis pre-
ponderance, were observed94. The authors argued
that the abnormal findings were unlikely to have been
the result of unspecific neurotoxicity. Two further
studies have reported colour vision deficiencies in
the blue-yellow axis for phenytoin-treated epilepsy
patients95, 96. It is known that the short-wavelength
sensitive pathways are highly susceptible to retinal
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disease, light and chemicals, decreasing their respon-
siveness149, moreover, depression of this pathway is
generally considered as an indicator of retinal dys-
function possibly brought on by the alteration of
neurotransmitters via AED therapy96.
Ethosuximide
The complete mechanistic action of ethosuximide is
unclear. However, it appears to lead to altered neu-
rotransmitter release, control of calcium into nerve
terminals and modulation of sodium and chloride con-
ductance. Apart from diplopia, which is a common
non-specific visual effect often associated with AEDs,
no adverse visual side-effects associated with this drug
have been reported in the literature, however, reports
of efficacy, adverse reactions and toxicity are limited.
Lamotrigine
Lamotrigine, an AED that is chemically distinct from
other anticonvulsants, acts primarily through the in-
hibition of use-dependent voltage-sensitive sodium
channels thus resulting in stabilisation of the presy-
naptic membrane150 and inhibiting the release of ex-
citatory neurotransmitters, particularly glutamate103.
The drug may also inhibit voltage-activated cal-
cium currents, and these combined properties con-
tribute to its wide spectrum of efficacy for epileptic
seizures.
Diplopia can occur in cases of acute toxicity re-
sulting from the pharmacological interaction of lam-
otrigine co-administered with carbamazepine151, 152,
and when lamotrigine is administered alone at high
doses153. In a pooled comparison of two clinical
databases of children and adolescents with epilepsy,
diplopia was reported as an adverse event in 5.4% of
patients treated with lamotrigine compared to 0.6% re-
ceiving placebo154. Moreover, in a multicentre trial of
566 patients treated with add-on lamotrigine therapy,
transient diplopia was amongst the adverse effects
reported155. Rotary nystagmus has been described
following overdose with lamotrigine156, however, a
comparison of carbamazepine and lamotrigine in a
group of healthy volunteers revealed altered saccadic
eye movements and smooth pursuit eye movements
with carbamazepine, but not lamotrigine157.
In a visual electrophysiological investigation of the
newer AEDs, abnormal pattern ERGs were apparent
in 2 out of 13 patients treated with lamotrigine, and of
those, an abnormal P100 VEP was apparent in 1143.
In contrast, a comparison of the electrophysiological
effects of phenytoin and lamotrigine revealed no evi-
dence of altered VEPs for either drug158.
Wohlrab et al.159 carried out Goldmann perimetry
in a number of children with epilepsy treated with
and without vigabatrin and identified a patient with
concentric visual field constriction who had been
treated only with sodium valproate and lamotrigine.
No other reports of visual field constriction have
been published. Furthermore, in Steinhoff et al.’s4
investigation of the effect of anticonvulsant drug ther-
apy on visual perception, no significant effects were
identified in healthy volunteers receiving the drug.
Levetiracetam
The precise mechanism by which levetiracetam ex-
erts its antiepileptic effect is unknown: it does not
appear to work through any recognised excitatory or
inhibitory route103. Laboratory studies have shown,
however, that levetiracetam reverses the effects of
negative allosteric modulators of GABA-gated cur-
rents and inhibits high-voltage-activated N-type cal-
cium currents in some cultured neurones160. In a
review of the European and the USA continuation
data for all epilepsy patients included in clinical trials
and exposed to levetiracetam between 1991 and 1999,
visual abnormalities were not among the adverse
effects described that lead to withdrawal161.
CONCLUSION
Of the anticonvulsive drugs commonly prescribed in
the UK, the large majority are associated with some
adverse visual effects. Many of these effects provide
an early indication of drug toxicity, over-dosage and
long-term use whereas others are thought to be re-
lated to the individual mechanistic properties of the
drugs and can be observed at therapeutic levels. Drugs
that act on the GABAergic pathway, especially viga-
batrin, appear to be particularly likely to result in vi-
sual symptoms.
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